Genmab — November 2020
-
-
Der er kø ved indgangen til dagens auktion
-
over 2400!
-
- 21 kr. og 66.000 aktier
-
2347
-
Så slog vi også NBI med 1 % pp
-
Nej, men det gjorde Genmab på OMX og derfor sammenligningen
-
Mens vi venter: Meld dig til Q&A med Genmab: https://www.proinvestor.com/index.php?p=q-and-a&groupid=125
-
Det tager kun få sekunder.
-
pil op
-
? Børsen?
-
Genmab overgår forventninger i tredje kvartal/Børsen
-
-
-
Is this one new? JNJ-70218902
• Phase 1 study in advanced stage solid tumors ongoing
• Developed by Janssen under the DuoBody technology collaboration
/ JNJ-70218902 is a bispecific antibody created by Janssen using Genmab's DuoBody technology. It is
being investigated in a Phase 1 clinical study for the treatment of advanced stage solid tumors.
Third Quarter 2020 Update
• September: A Phase 1 study of JNJ-70218902 in patients with advanced solid tumors was
initiated.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind